JP2012515163A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515163A5
JP2012515163A5 JP2011545487A JP2011545487A JP2012515163A5 JP 2012515163 A5 JP2012515163 A5 JP 2012515163A5 JP 2011545487 A JP2011545487 A JP 2011545487A JP 2011545487 A JP2011545487 A JP 2011545487A JP 2012515163 A5 JP2012515163 A5 JP 2012515163A5
Authority
JP
Japan
Prior art keywords
composition
matrix
phase
delivery system
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545487A
Other languages
English (en)
Japanese (ja)
Other versions
JP5702306B2 (ja
JP2012515163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/020629 external-priority patent/WO2010081079A2/en
Publication of JP2012515163A publication Critical patent/JP2012515163A/ja
Publication of JP2012515163A5 publication Critical patent/JP2012515163A5/ja
Application granted granted Critical
Publication of JP5702306B2 publication Critical patent/JP5702306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545487A 2009-01-12 2010-01-11 糖尿病治療のための組成物及び方法 Active JP5702306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US61/143,951 2009-01-12
US29377310P 2010-01-11 2010-01-11
PCT/US2010/020629 WO2010081079A2 (en) 2009-01-12 2010-01-11 Composition and method for treatment of diabetes
US61/293,773 2010-01-11

Publications (3)

Publication Number Publication Date
JP2012515163A JP2012515163A (ja) 2012-07-05
JP2012515163A5 true JP2012515163A5 (cg-RX-API-DMAC7.html) 2013-02-14
JP5702306B2 JP5702306B2 (ja) 2015-04-15

Family

ID=42317190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545487A Active JP5702306B2 (ja) 2009-01-12 2010-01-11 糖尿病治療のための組成物及び方法

Country Status (23)

Country Link
US (2) US8470885B2 (cg-RX-API-DMAC7.html)
EP (1) EP2376077B1 (cg-RX-API-DMAC7.html)
JP (1) JP5702306B2 (cg-RX-API-DMAC7.html)
KR (4) KR20170034928A (cg-RX-API-DMAC7.html)
CN (1) CN102355896A (cg-RX-API-DMAC7.html)
AU (1) AU2010203413B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1006145B8 (cg-RX-API-DMAC7.html)
CA (1) CA2748827C (cg-RX-API-DMAC7.html)
CL (1) CL2011001692A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119010T1 (cg-RX-API-DMAC7.html)
DK (1) DK2376077T3 (cg-RX-API-DMAC7.html)
EA (1) EA022631B1 (cg-RX-API-DMAC7.html)
ES (1) ES2628233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170886T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034551T2 (cg-RX-API-DMAC7.html)
LT (1) LT2376077T (cg-RX-API-DMAC7.html)
MX (1) MX2011007393A (cg-RX-API-DMAC7.html)
PL (1) PL2376077T3 (cg-RX-API-DMAC7.html)
PT (1) PT2376077T (cg-RX-API-DMAC7.html)
RS (1) RS56054B1 (cg-RX-API-DMAC7.html)
SI (1) SI2376077T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700278T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010081079A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
ES2705236T3 (es) 2010-05-12 2019-03-22 Univ Columbia Procedimientos para producir células enteroendocrinas que producen y secretan insulina
KR20140030171A (ko) * 2011-05-02 2014-03-11 바이오키어 인코포레이티드 당뇨병 치료를 위한 조성물 및 치료법
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
BR112014011898A2 (pt) * 2011-11-21 2017-05-16 Emmaus Medical Inc métodos e composições para o tratamento de diabetes e sintomas relacionados
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
EP4194001B1 (en) * 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019165309A1 (en) 2018-02-23 2019-08-29 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US20210046011A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) * 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PT1506963E (pt) 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
BRPI0609464A2 (pt) 2005-05-23 2010-04-13 Japan Tobacco Inc composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
DE102005046237A1 (de) 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
ITMI20052000A1 (it) * 2005-10-21 2007-04-22 Promefarm S R L Compressa gastroresitente a base di butirrato di sodio
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
CA2673054C (en) * 2006-12-15 2016-05-10 Tima Foundation Novel compositions and uses thereof
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
RU2505292C2 (ru) 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same

Similar Documents

Publication Publication Date Title
Singh et al. Carboxymethyl cellulose-rosin gum hybrid nanoparticles: An efficient drug carrier
Das et al. Modified biopolymer-dextrin based crosslinked hydrogels: application in controlled drug delivery
Rao et al. Novel thermo/pH sensitive nanogels composed from poly (N-vinylcaprolactam) for controlled release of an anticancer drug
Levis et al. Use of coated microtubular halloysite for the sustained release of diltiazem hydrochloride and propranolol hydrochloride
Wang et al. Glucose-responsive micelles from self-assembly of poly (ethylene glycol)-b-poly (acrylic acid-co-acrylamidophenylboronic acid) and the controlled release of insulin
Sullad et al. Novel pH-sensitive hydrogels prepared from the blends of poly (vinyl alcohol) with acrylic acid-graft-guar gum matrixes for isoniazid delivery
Chatterjee et al. Stimuli-responsive hydrogels: An interdisciplinary overview
Rao et al. pH sensitive halloysite-sodium hyaluronate/poly (hydroxyethyl methacrylate) nanocomposites for colon cancer drug delivery
Wong Alginate graft copolymers and alginate–co-excipient physical mixture in oral drug delivery
HRP20171506T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
JP2013508033A5 (cg-RX-API-DMAC7.html)
JP2013514977A5 (cg-RX-API-DMAC7.html)
CN101265312A (zh) 两亲性三嵌段共聚物及制备方法和应用
JP2017524743A5 (cg-RX-API-DMAC7.html)
Liu et al. Synthesis of chitosan-based nanohydrogels for loading and release of 5-fluorouracil
HRP20170886T1 (hr) Smjesa i metoda za liječenje dijabetesa
CN103748139A (zh) 用于递送生物活性剂的包含生物可降解的聚酯酰胺共聚物的微米颗粒或纳米颗粒
Thakker et al. Inter-polymer complex microspheres of chitosan and cellulose acetate phthalate for oral delivery of 5-fluorouracil
Liu et al. Preparation and characterization of glutaraldehyde cross-linked O-carboxymethylchitosan microspheres for controlled delivery of pazufloxacin mesilate
Hu et al. Degradation and degradation-induced re-assembly of PVP-PCL micelles
CN102633959A (zh) 一种具有pH响应性的梳状共聚物及其制法和应用
JP2015120756A5 (cg-RX-API-DMAC7.html)
Shahid et al. pH-Responsive nanocomposite based hydrogels for the controlled delivery of ticagrelor; in vitro and in vivo approaches
Chang et al. Thermo-responsive shell cross-linked PMMA-bP (NIPAAm-co-NAS) micelles for drug delivery
Pandey et al. D/O Segar Singh